Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Hematology"
DOI: 10.1007/s12185-022-03320-0
Abstract: The glycoengineered, humanized anti-CD20 antibody obinutuzumab is indicated for previously untreated or relapsed/refractory CD20-positive follicular lymphoma (FL). However, the effectiveness of obinutuzumab retreatment in relapsed/refractory FL after prior obinutuzumab-containing therapy is unclear. To address this… read more here.
Keywords: obinutuzumab resistant; antitumor activity; day; resistant tumors ... See more keywords